Share Name Share Symbol Market Type Share ISIN Share Description
Medical Solutions LSE:MLS London Ordinary Share GB0009739649 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 7.72p 0.00p 0.00p - - - 0 06:32:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services - - - - 15.46

Medical Solutions Share Discussion Threads

Showing 13751 to 13766 of 13775 messages
Chat Pages: 551  550  549  548  547  546  545  544  543  542  541  540  Older
Ok found it. SBS now
My parent have some old certs in this company. Can anyone tell me what actually happened here please? Did they go bust, LBO, takeover? Any info appreciated Thanks
______________________________________________________________________________________________________ ............ The Future of the Pharma Industry --------- Personalized/Precision Medicine ............. ______________________________________________________________________________________________________ Personalized/Precision Medicine is a massive growth area as BIG PHARMA companies are increasingly taking positions in companies that provide the testing/products/services that are needed to get new drug compounds approved that provide better targeted efficacy for patients in a quicker and more cost effective timeframe. hTTp:// ............... Costs are coming down as new technologies are being utilized ............... Since 2006,Clinical Phase I drugs developed without the use of biomarkers have an 8.4 percent chance of gaining approval. Today the success rate is three times higher – 25.9 percent – for development programs that did employ biomarkers. hTTp:// In 2016 .... 50%+ more targeted therapy launches are taking place than in 2015 hTTp:// DNA next generation sequencing (NGS) is also going to play an increasingly important part in the growth of Personalized/Precision Medicine. _______________________________________________________________________________________________________ ............................. The FDA and Personalized/Precision Medicine ............................. _______________________________________________________________________________________________________ The FDA refer to Personalized Medicine as 'Precision Medicine' 8th March 2016 hTTp:// hTTp:// The FDA will now have to move quickly by implementing/mandating the way genetic testing and DNA next generation sequencing (NGS) will take place within the bounds of its goals for the advent of a meaningful move to personalized/precision medicine. Hence I think Cyprotex providing such testing and services from its labs with the aid of Source BioScience expertise will help BOTH companies _______________________________________________________________________________________________________ ................ The Source BioScience Group and The Cyprotex Group ............. _______________________________________________________________________________________________________ Both of these companies state that they are committed to ''increasing value for shareholders'' Both of these companies operate in the Pharma Biotech sector, both have considerable presence in the UK and also in the USA (where SBS wants to become the leading DNA Sequencing provider : see finals extract to follow) DNA Sequencing and Genomic Services ''The DNA Sequencing and Genomic Services business provides ultra-fast DNA sequencing services delivered by the Group's international network of laboratories and distributors to academic research groups, biotechnology and pharmaceutical companies. Source BioScience's ambition is to become the leading commercial provider of DNA sequencing in the UK and the USA. The Group's ultra-fast service, with data delivery times of less than ten hours, and international laboratory network continues to power the growth of this business. Over 1 million customer samples for DNA sequencing were analysed during the year, an increase of 15% compared with the prior year. In 2015 the DNA sequencing service was launched from the Group's facilities in Atlanta for customers in the south east of the USA.'' Both of these companies state that they are committed to ''increasing value for shareholders'' SourceBioScience : From last weeks results Outlook ''We believe that the Group has a very strong business model and opportunities for further growth are apparent across the Laboratory Services and Products divisions. The Board's strategy is to expand the service and product offering, enabling greater market penetration, with the objective of delivering increasing value for shareholders. The aim is to achieve this through continued organic growth from the enlarged infrastructure in addition to further, carefully selected acquisitions when the opportunities arise, building on the strong foundations now established in the business.'' Cyprotex page 18 Commitment to increase shareholder value hTTp:// The top two Institutions of The SourceBioScience Group are : Harwood Capital ............... 23.5% Henderson Global Investors .... 20.0% The same two Institutions own shares in The Cyprotex Group Harwood Capital ............... 29.4% Henderson Global Investors .... 5.0% (in the form of Alphagen Volantis notes) I put it to the above companies and Institutional funds that to deliver increased shareholder value for both companies the following should be undertaken . Source BioScience and Cyprotex should enter into a 50/50 strategic partnering deal. The objective would be increase turnover in both companies. 1. By utilizing cross selling each others services to each others clients. 2. By the utilization/expansion of existing Cyprotex Lab space in both Kalamazoo and in Watertown Labs so as to provide DNA Ultra Fast Sequencing Services from both Locations. Remember SBS offer a ultra fast service that is 10 hours for delivery of data ... thus further USA Geographical locations are going to be needed. 3. By the provision of a cold storage facility in both Labs Number 2 could be undertaken on a 50/50% basis for an agreed period , say 3 to 5 years Number 3. could follow on if 1. and 2. proved to be fruitful Cyprotex has recently created a new BioSciences Division , it is growing and offers complementary assays in areas where SourceBioScience has none. Cyprotex has a massive range of ADME Tox assays where SourceBioScience has next to none having all but exited that growth market some 3 years ago. I believe that a shared 50/50% deal would increase the shareholder value in the following ways a) On the day/s of the announcements the share prices of both companies should rise by around 10% ( this makes the raising of further funds for new acquisitions better for existing shareholders - less dilutive affect ) b) It is not unrealistic to assume the turnover of both companies on a shared basis - equal input/work/selling - would rise 5% in the first year due to such a deal , and then grow another 5% over the next 2 further years. If number 3. above was then implemented in a similar fashion(after year.3 , with the creation of diagnostic testing services from USA Cyprotex Labs , then another 5% to 10% could be added over the following 3 years. All of the above and more could be written in as part of the strategic partnership deal - investors would like it as it makes sense and increases market reach/penetration for both at a minimum cost with an agreed split of monies 50/50%. It's a win/win ..... please make it happen
Well if it is SBS it is well disguised as something else. ADVFN & Moneyextra don't recognise SBS - the Share Centre does. So any suggestions on finding out how it is performing?
Thanks Andrew
SBS.L on Yahoo, presumably LSE:SBS here.
Anyone - What is the new ticker please?
new ticker?
Director pre results?///.. Maybe this is the start of the build up in confidence.
1.3million shares traded today- whose?
Not a chartist buywell2 but it certainly looks to be trending up and ready for the next leg, hopefully on results.
Well it'd be the first time the price ever went up on results day if we were scrib??
what a great day to announce the results - St Patrick day! lets hope we're all sinking a few celebratory Guiness on that day!
Medical Solutions plc ('Medical Solutions' or 'the Company') NOTICE OF RESULTS Medical Solutions plc, (LSE: MLS), the provider of expert, quality services and products to the healthcare, pharma biotech and life sciences research sectors, expects to announce its preliminary results for the year ended 31 December 2007 on 17 March 2008.
Warranty Turnpyke days and Michael Walters ! ... Lol ... Have to agree it does look like good times ahead at MLS at long last ! Can't make my mind up though who in my opinion over the years as done more damage to MLS the NHS or those Highly Paid Comedians/Pr Experts " Twose , Green and Longstaff " ? ... Think i'll take 50/50 , Phone A Friend or Ask The Audience ... Lol
paulo dicanio
Well, I'm with SuicideSid, it looks like after all this time and all the disappointments we may be looking ahead at a good future. This share has cost me a bundle in notes as well as perspiration but we're still here SS2 so bring it on. Crikey fancy remembering turnpyke days!!
Chat Pages: 551  550  549  548  547  546  545  544  543  542  541  540  Older
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180123 09:50:03